Clinical Trial Update: A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers [Phase 2]

View source ↗

Summary

Phase II study evaluating the combination of ipilimumab and nivolumab for rare cancers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer
• Malignant Tumor of Female Reproductive System
• Neuroendocrine Tumors

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Olivia Newton-John Cancer Research Institute | Conditions: Gastrointestinal Cancer, Neuroendocrine Tumours | Phase 2 | Status: COMPLETED